Cinzia Antognelli

Prof. Cinzia Antognelli

University of Perugia, Department of Experimental Medicine
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2003 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
Rita RomaniRita Romani
Rita Romani
Cinzia AntognelliCinzia Antognelli
Cinzia Antognelli
FBFrancesca Baldracchini
Francesca Baldracchini
ASAlessandra De Santis
Alessandra De Santis
GIGloria Isani
Gloria Isani
GRGabriella Rosi
Gabriella Rosi

1 March 2018 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
LMLorella Marinucci
Lorella Marinucci
SBStefania Balloni
Stefania Balloni
KFKatia Fettucciari
Katia Fettucciari
MBMaria Bodo
Maria Bodo
VTVincenzo N. Talesa
Vincenzo N. Talesa
Cinzia AntognelliCinzia Antognelli
Cinzia Antognelli

1 February 2018 in Free Radical Biology and Medicine
Verified
Journal Article
Open access
Cinzia AntognelliCinzia Antognelli
Cinzia Antognelli
ETEliana Trapani
Eliana Trapani
SMSimona Delle Monache
Simona Delle Monache
APAndrea Perrelli
Andrea Perrelli
MDMartina Daga
Martina Daga
Saverio Francesco RettaSaverio Francesco Retta
Saverio Francesco Retta
KRIT1 (CCM1) is a disease gene responsible for Cerebral Cavernous Malformations (CCM), a major cerebrovascular disease of proven genetic origin affecting 0.3-0.5% of the population. Previously, we demonstrated that KRIT1 loss-of-function is associated with altered redox homeostasis and abnormal activation of the redox-sensitive transcription factor c-Jun, which collectively result in pro-oxidative, pro-inflammatory and pro-angiogenic effects, suggesting a novel pathogenic mechanism for CCM disease and raising the possibility that KRIT1 loss-of-function exerts pleiotropic effects on multiple redox-sensitive mechanisms. To address this possibility, we investigated major redox-sensitive pathways and enzymatic systems that play critical roles in fundamental cytoprotective mechanisms of adaptive responses to oxidative stress, including the master Nrf2 antioxidant defense pathway and its downstream target Glyoxalase 1 (Glo1), a pivotal stress-responsive defense enzyme involved in cellular protection against glycative and oxidative stress through the metabolism of methylglyoxal (MG). This is a potent post-translational protein modifier that may either contribute to increased oxidative molecular damage and cellular susceptibility to apoptosis, or enhance the activity of major apoptosis-protective proteins, including heat shock proteins (Hsps), promoting cell survival. Experimental outcomes showed that KRIT1 loss-of-function induces a redox-sensitive sustained upregulation of Nrf2 and Glo1, and a drop in intracellular levels of MG-modified Hsp70 and Hsp27 proteins, leading to a chronic adaptive redox homeostasis that counteracts intrinsic oxidative stress but increases susceptibility to oxidative DNA damage and apoptosis, sensitizing cells to further oxidative challenges. While supporting and extending the pleiotropic functions of KRIT1, these findings shed new light on the mechanistic relationship between KRIT1 loss-of-function and enhanced cell predisposition to oxidative damage, thus providing valuable new insights into CCM pathogenesis and novel options for the development of preventive and therapeutic strategies.


20 April 2009 in BMC Cancer
Verified
Journal Article
Open access
PDF file
Cinzia AntognelliCinzia Antognelli
Cinzia Antognelli
CBChiara Del Buono
Chiara Del Buono
VLVienna Ludovini
Vienna Ludovini
SGStefania Gori
Stefania Gori
VTVincenzo N Talesa
Vincenzo N Talesa
ARAntonio Rulli
Antonio Rulli
Estrogens, environmental chemicals with carcinogenic potential, as well as oxidative and carbonyl stresses play a very important role in breast cancer (BC) genesis and progression. Therefore, polymorphisms of genes encoding enzymes involved in estrogen biosynthesis pathway and in the metabolic activation of pro-carcinogens to genotoxic intermediates, such as cytochrome P450C17α (CYP17), endogenous free-radical scavenging systems, such as glutathione S-transferase (GSTP1) and paraoxonase 1 (PON1), and anti-glycation defenses, such as glyoxalase I (GLO1), could influence individual susceptibility to BC. In the present case-control study, we investigated the possible association of CYP17 A1A2, GSTP1 ILE105VAL, PON1 Q192R or L55M, and GLO1 A111E polymorphisms with the risk of BC.

24 March 2005 in The Prostate
Verified
Journal Article
Closed access
PDF file
Cinzia AntognelliCinzia Antognelli
Cinzia Antognelli
LMLuigi Mearini
Luigi Mearini
VTVincenzo Nicola Talesa
Vincenzo Nicola Talesa
AGAntonella Giannantoni
Antonella Giannantoni
EMEttore Mearini
Ettore Mearini